FDA “Data Steward” Role Suggested By Industry In Lieu of Direct Release of NDA/BLAs
This article was originally published in RPM Report
Executive Summary
FDA surprised a number of industry observers in June when the agency interpreted a call for “regulatory science” improvements from FDASIA to include release of NDA and BLA data. Instead of just objecting outright to the proposal, however, a number of biopharma groups have suggested other ways in which FDA can mine useful information from the dataset through collaborative relationships.
You may also be interested in...
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.
As Sickle Cell Gene Therapies Move To Market, Health Inequities Could Help Pricing Debate
Positive tandem ICER reviews for bluebird bio’s and Vertex/CRISPR’s gene therapies show the impact that concerns about addressing racial inequities could create a favorable context for products as they enter pricing and coverage discussions.
The Evolving Door? What Having A ‘Big Data’ Commissioner Might Mean For US FDA
Robert Califf’s nomination to return as FDA commissioner will raise protests about a ‘revolving door’ pathway between industry and agency. But, in this case, it may be more apt to talk about how Califf’s time outside FDA led to evolving views on the role of big data in drug regulation.